CURRICULUM VITAE
(ESMO-ID: 81500)
(ASCO-ID: 272603)
(IASLC-ID: 424795)
(IAP-ID: L/2014/B-1368)
(PHO-ID: L/2014/794)
(INPOG/R/2015/22)
Personal Details
Name : Dr. Bivas Biswas
Qualifications : MBBS, MD (Pediatrics, AIIMS),
DM (Medical Oncology, AIIMS)
ORCID ID : 0000-0002-6101-5500
Education and Qualifications:
S.No. Degree University Year
1. MBBS Calcutta Medical College,
Calcutta University, Calcutta, India
1999-2005
2. Junior Resident
(Neurosurgery)
Calcutta Medical College,
Calcutta University, Calcutta, India
2005-2006
3. M.D.(Pediatric
Medicine)
All India Institute Medical Sciences, New
Delhi, India
2006-2009
4. Senior Resident All India Institute Medical Sciences, New 2009-2010
(Medical Oncology) Delhi, India
5. D.M. (Medical
Oncology)
All India Institute of Medical Sciences
(AIIMS), New Delhi, India
2010-2013
Work experience:
1. Junior residency (non-academic) in Neurosurgery, Calcutta Medical College. From
May’2005- Feb’2006
2. Junior Residency (MD Pediatrics), AIIMS, New Delhi: from July’2006 – June’2009
3. Senior residency (non-academic) in Medical Oncology, AIIMS, New Delhi. From
July’2009 – June’2010
4. Senior resident (DM Medical Oncology), AIIMS, New Delhi: from July’2010 –
June’2013
5. Consultant (Medical Oncology), Apollo Gleneagles Hospital. 58, Canal Circular Road,
Kolkata-700054. From July’2013 – May’2014.
6. Consultant (Medical Oncology), Tata Medical Center, Action Area I, Newtown, New
Town, Kolkata - 700160, West Bengal. From June’2014 – Nov’2015.
7. Assistant Professor in Department of Medical Oncology, Dr. B.R.A. I.R.C.H, AIIMS,
New Delhi-110029. From Dec’2015 – June’2016.
8. Current workplace (Since July’16): Consultant Medical Oncologist at Tata Medical
Center, Action Area I, Newtown, New Town, Kolkata - 700160, West Bengal.
Awards and achievements:
1. Gold medal in Pediatrics (MBBS)
2. Shakuntala Jolly Gold medal in Medical Oncology (DM course)
3. Passed European Society for Medical Oncology (ESMO) Exam 2012
4. Awarded European Society for Medical Oncology (ESMO) Translational Research Unit
(TRU) fellowship on 21st – 24
th October’2013
5. Received ISMPO award in 1st Indian Cancer Congress (ICC)’2013
6. Awarded SIOP Scholarship in the year 2016 to present paper to the 48th Annual meeting of
SIOP in Dublin, Ireland, 16-19th October’2016.
7. Selected in 2016 Australia and Asia Pacific Clinical Oncology Research Development
(ACORD) Workshop
Academic positions:
1. Teacher & mentor for National Board of Examination [DNB] accredited post-doctoral
fellowship program in Medical Oncology
2. Assessor of DNB examination conducted by NBE.
3. Section Editor in Indian Journal of Medical & Pediatric Oncology [IJMPO]
4. Reviewer in Journal of Thoracic Oncology [ JTO], Indian Journal of Pediatrics [IJP], Indian
Journal of Medical & Pediatric Oncology [ IJMPO], BMC cancer, Journal of Urology, BMJ
palliative & supportive care
International travel grants recipients:
1. Awarded International Travel grant from ESMO to participate in ESMO Preceptorship
on Gastric Cancer, 20-21 December” 2013, Singapore
2. Awarded International Travel grant to present paper in “37th ESMO (Vienna, Austria,
2012)” from Department of Science and Technology, Govt. of India
3. Awarded International Travel grant from ESMO to attend “Personalized medicine 2013
- Signalling Pathways Targeting the HER/EGFR family: Focus on breast, lung and
colorectal cancers, 2013, Sitges, Spain”.
4. Awarded International Travel grant to present paper in “ASCO Annual Meeting’2013,
Chicago, USA” from CSIR, Govt. of India.
5. Awarded International Travel grant to present papers in “45th Congress of the
International Society of Paediatric Oncology (SIOP)’ 2013” from ICMR, Govt. of India.
6. Awarded International Travel grant to attend “ESMO Symposium on Immuno-Oncology
2013: Advances in cancer immunotherapy; from vaccines to antibodies and cell therapies”.
7. Awarded International Travel grant from ESMO to participate in “ESMO Preceptorship
on Immuno-oncology, 2-3 October’2015, Prague.
8. Awarded International Travel grant from ESMO to participate in “ESMO Preceptorship
on NSCLC, 13-14 December’2016, Singapore.
9. Awarded International Travel grant from ESMO to participate in “ESMO Preceptorship
on Prostate cancer, 15-16 December’2016, Singapore.
PUBLICATIONS
Original articles:
1. Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SVS, Agarwala S, Mohanti BK, Sharma
MC, S Vishnubhatla, Bakhshi S. Developing a Prognostic Model for Localized Ewing
Sarcoma Family of Tumors: a Single Institutional Experience of 224 Cases Treated with
Uniform Chemotherapy Protocol. J Surg Oncol. 2015;111(6):683-9
2. Biswas B, Thakar A, Mohanti BK, S Vishnubhatla, Bakhshi S. Prognostic factors in head and
neck Ewing sarcoma family of tumors. Laryngoscope. 2015; 125(3):E112-7.
3. Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SVS, Agarwala S, Sharma DN, Thulkar S,
S. Vishnubhatla, Bakhshi S. Hypoalbuminaemia is an Independent Predictor of Poor
Outcome in Metastatic Ewing's Sarcoma Family of Tumours: A Single Institutional
Experience of 150 Cases Treated with Uniform Chemotherapy Protocol. Clin Oncol (R Coll
Radiol). 2014; 26(11): 722–729.
4. Biswas B, Shukla NK, Deo SVS, Agarwala S, Sharma DN, Sreenivas Vishnubhatla, Bakhshi
S. Evaluation of outcome and prognostic factors in Extraosseous Ewing sarcoma. Pediatric
Blood Cancer. 2014; 61(11):1925-31.
5. Biswas B, Rastogi S, Khan SA, Mohanti BK, Sharma DN, Sharma MC, Mridha AR, Bakhshi
S. Outcome and Prognostic Factors in Ewing's family Tumors of the Extremities. J Bone
Joint Surg Am. 2014; 96(10):841-849.
6. Biswas B, Agarwala S, Shukla NK, Deo SVS,
Sharma DN, Thulkar S, Sreenivas
Vishnubhatla, Bakhshi S. Evaluation of outcome and prognostic factors in thoracic primitive
neuroectodermal tumor: a study of 84 cases. Ann Thorac Surg. 2013; 96(6):2006-14.
7. Biswas B, Agarwala S, Rastogi S, Khan SA, Mohanti BK, Sharma DN, Pathy S, Bakhshi S.
High Burden of Metastases and Poor Outcome in Pelvic PNET. Pediatric Blood Cancer.
2013; 60(9):E97-9.
8. Biswas B, Dabkara D, Ganguly S, Ghosh J, Gupta S, Sen S, Chatterjee M, Basu A,
Mukherjee S. (2021) Outcome of testicular non-seminomatous germ cell tumours: report
from a tertiary cancer centre in eastern India. ecancer. 2021; 15 1204
9. Biswas B, Sharma M.C, Mridha AR, Bakhshi S. Expression of Cathepsin L in tumor cells
and tumor associated macrophages in patients with Ewing sarcoma family of tumors: A pilot
study. Indian J Pathol Microbiol 2015, 58(2): 170-74.
10. Biswas B, Bakhshi S. Management of Ewing sarcoma family of tumors: current scenario and
unmet need. World J Orthop. 2016; 7(9): 527-538.
11. Biswas B, Dabkara D, Sengupta M, Ganguly S, Ghosh J, Arunsingh S M, Sen S.
Multimodality treatment outcome in patients with primary malignant mediastinal germ cell
tumor in adults. Cancer Rep (Hoboken). 2020 Oct 8:e1306. doi: 10.1002/cnr2.1306.
12. Patel A, Batra
U, Prasad
KT, Dabkara
D, Ghosh
J, Sharma
M, Singh N,
Suresh P, Jain
P, Malik
PS, Choudhary
P, Ganguly
S, Khurana
S, Shivashankara Ms
,
Bothra N, Muthu
V, Biswas B. Real world experience of treatment and outcome in ALK-
rearranged metastatic non-small cell lung cancer: A multicenter study from India. Current
Problems in Cancer; Mar’2020 [DOI: 10.1016/j.currproblcancer.2020.100571].
13. Prasad KT, Muthu
V, Biswas
B, Malik
PS, Dabkara
D, Ganguly
S, Ghosh
J, Kataria
B,
Khurana S, Verma
S, Singh N. Utility and safety of maintenance chemotherapy in advanced
non–small cell lung cancer across various performance status categories: real-world
experience. Current Problems in Cancer; Mar’2020
[DOI: 10.1016/j.currproblcancer.2020.100565].
14. Arora N, Mukherjee G, Biswas B, Gupta P, Saha K, Vinarkar S, Banerjee S, Chowdhury S.S,
Parihar M, Midha D, Lingegowda D, Chatterjee S, Arunsingh S M, Ganguly S, Dabkara D,
Mishra DK. Next generation sequencing in Lung cancer: An Initial Experience from India.
Current Problems in Cancer; Feb’2020 [DOI: 10.1016/j.currproblcancer.2020.100562].
15. Kumar S, Joga S, Biswas B, Dabkara D, Prasad KT, Singh N, Malik PS, Khurana S, Ganguly
S, Muthu V, Batra U. Immune checkpoint inhibitors in advanced non–small cell lung cancer:
A metacentric experience from India. Current Problems in Cancer; Jan’2020
[DOI: 10.1016/j.currproblcancer.2020.100549].
16. Sharma A, Kataria B, Biswas B, Bakhshi S, Pushpam D. Oral metronomic chemotherapy is a
cost effective alternative to pazopanib in advanced soft tissue sarcoma. Journal of Oncology
Pharmacy Practice. March 2021. doi:10.1177/10781552211000113
17. Ghosh J, Chatterjee M, Ganguly S, Dabkara D, Biswas B. Outcomes of metastatic
neuroendocrine carcinoma of the gallbladder. ecancer 2021, 15:1174; DOI:
https://doi.org/10.3332/ecancer.2021.1174.
18. Ghosh J, Chatterjee M, Ganguly S, Datta A, Biswas B, Mukherjee G, Agarwal S, Ahmed R,
Chatterjee S, Dabkara D (2021) PDL1 expression and its correlation with outcomes in non-
metastatic triple-negative breast cancer (TNBC) ecancer 15 1217.
19. Ganguly S, Ghosh J, Gehani A, Basu A, Chatterjee M, Dabkara D, Biswas B. Non-small-cell
lung cancer metastasis to unusual sites: A retrospective case series. Cancer Res Stat Treat
2021;4:50-4.
20. Kumar A, Biswas B, Chopra A, Kapil A, Vishnubhatla S, Bakhshi S. Early Discontinuation
versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients with
Febrile Neutropenia, Before Recovery of Counts: A Randomized Controlled Trial (DALFEN
Study). Indian J Pediatr, June 2020.
21. Ghosh J, Ganguly S, Mondal D, Pandey P, Dabkara D, Biswas B. Perspective of Oncology
Patients During COVID-19 Pandemic: A Prospective Observational Study From India. JCO
Global Oncol 6:844-851.
22. Ganguly S, Biswas B, Bhattacharjee S, Ghosh J, Mukhopadhyay S, Midha D, Dabkara D.
Clinocopathological characteristics and treatment outcome in small cell lung cancer: a single
institutional experience from India. Lung India, 37 (2), 134-139
[10.4103/lungindia.lungindia_370_19]
23. Puspam D, Garg V, Ganguly S, Biswas B. Management of Refractory Pediatric Sarcoma:
Current Challenges and Future Prospects. OncoTargets and Therapy 13:5093-5112.
24. Dabkara D, Ganguly S, Ghosh J, Mukherjee S, Gupta S, Mallick I, Mukherjee S, Midha D,
Chatterjee M, Basu A, Hasan A, Biswas B. Clinico-pathological characteristics, prognostic
factors and treatment outcomes of seminomatous germ cell tumors from a tertiary cancer
center in Eastern India. Natl Med J India. 2019 (in press).
25. Biswas B, Ghadyalpatil N, Krishna MV, Deshmukh J. A review on adverse event
profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell
lung cancer patients. Indian J Cancer. 2017 Dec; 54(Supplement):S55-S64. doi:
10.4103/ijc.IJC_589_17.
26. Biswas B, Sharma A, Makharia GK, Thulkar S, Arava S, Bahl A, Chaudhary S.
Immunoproliferative small intestinal disease: report of 6 cases. Tropical Gastroenterology
2014; 35(4):269–272.
27. Prabhash K, Advani SH, Batra U, Biswas B, Chougule A, Ghosh M, Muddu VK, Sahoo TP,
Vaid A. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for
Molecular Testing. Advances in Therapy, March 2019 [DOI: 10.6084/m9.figshare.7680170
28. Verma H, Sehgal K, Panchal K.B, Chakraborty S, Biswas B, Mukherjee G, Midha D, Biswas
G. Presentation and Management of Dermatofibrosarcoma Protuberans: A Single Center
Protocol. Indian J of Surg Oncol, 11(1):35-40. doi: 10.1007/s13193-019-01007-3.
29. Ghosh A, Ghosh J, Midha D, Banerjee P, Chakraborti B, Roy A, Rai S, Mathai S, Ganguly
S, Dabkara D, Biswas B, Bhaumik J. Clinical and Pathological Characteristics and Outcomes
of Clear Cell Carcinoma of Ovary: A Tertiary Cancer Centre Data. Indian Journal of
Gynecologic Oncology, December 2019 [DOI: 10.1007/s40944-019-0314-1].
30. Patel A, Tiwari A, Biswas B, Sharma MC, Vishnubhatla S, Bakhshi S. Clinical Predictors
and Prognostic Model for Pediatric Lymphoblastic Lymphoma Treated with Uniform BFM90
Protocol: A Single-Center Experience of 65 Patients from Asia. Clinical lymphoma,
myeloma & leukemia, 19(6) [DOI: 10.1016/j.clml.2019.01.008].
31. Bakhshi S, Batra A, Biswas B, Dhawan D, Paul R, Sreenivas V. Aprepitant as an Add-on
Therapy in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double
Blind, Placebo-Controlled Trial. Support Care Cancer. 2015; 23(11):3229-37.
32. Hari P, Biswas B, Pandey R, Kalaivani M, Kumar R, Bagga A. Updated height- and
creatinine-based equation and its validation for estimation of glomerular filtration rate in
children from developing countries. Clin Exp Nephrol. 2012; 16(5): 697-705.
33. Kumar L, Cyriac SL, Tejomurtula TV, Bahl A, Biswas B, Sahoo RK, Mukherjee A, Sharma
O. Autologous Stem Cell Transplantation for Multiple Myeloma: Identification of Prognostic
Factors. Clin Lymphoma Myeloma Leuk. 2013; 13(1): 32-42.
34. Seth A, Mahapatra SK, Nayak B, Saini AK, Biswas B. Primitive neuroectodermal
tumors of kidney: Our experience in a tertiary care center. Indian J Cancer. 2016;
53(1): 109-12.
35. Dabkara D, Ganguly S, Biswas B, Ghosh J. Metronomic therapy in metastatic castrate-
resistant prostate cancer: Experience from a tertiary cancer care center. Indian Journal of
Cancer. 2018 Jan-Mar;55(1):94-97. doi: 10.4103/ijc.IJC_346_17
36. Ganguly S, Biswas B, Ghosh J,Dabkara D. Metastatic stomach cancer: Real world scenario
from a developing country. South Asian Journal of Cancer. 2018 Jul-Sep;7(3):171-174.
doi: 10.4103/sajc.sajc_2_18.
37. Mallick A, Das J, Shaw MK, Biswas B, Ray S. Prognostic value of metabolic tumor
parameters in pretreatment 18F-fluorodeoxyglucose positron emission tomography–
computed tomography scan in advanced non-small cell lung cancer. Indian J Nucl Med
2021;36:107-13.
Review article
1. Dabkara D, Mondal D, Ghosh J, Biswas B, Ganguly S. How I Treat Metastatic Hormone-
Sensitive Prostate Cancer? Ind J Med Paediatr Oncol 2021;42:100–107.
Correspondence:
1. Biswas B, Ganguly S, Ghosh J. Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Mar 25;384(12):1174-1175. doi: 10.1056/NEJMc2100225. PMID:
33761222.
2. Biswas B, Dabkara D, Ganguly S. Survival of patients with metastatic breast cancer with or
without locoregional therapy. Lancet Oncol. 2015 Dec;16(16):e586-7. doi: 10.1016/S1470-
2045(15)00453-2
3. Biswas B, Dabkara D. Bevacizumab in advanced angiosarcoma: what is the reality? J Clin
Oncol. 2016 Mar 1;34(7):764. doi: 10.1200/JCO.2015.64.2181.
4. Biswas B. Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With
Advanced Non–Small-Cell Lung Cancer in the Era of Personalized Medicine. J Clin Oncol.
2015; 33:524.
5. Biswas B, Dabkara D, Ganguly S, G Joydeep, Prasad E. Cytoreductive nephrectomy in
metastatic renal cell carcinoma in the era of targeted therapy: scientifically relevant or natural
selection? J Clin Oncol. 2017 Feb 6:JCO2016708156. doi: 10.1200/JCO.2016.70.8156.
6. Biswas B, Dabkara D, Ganguly S, G Joydeep, Prasad E. Adjuvant chemotherapy for upper
tract urothelial carcinoma: is there sufficient evidence? J Clin Oncol. 2017 May
4:JCO2017728600. doi: 10.1200/JCO.2017.72.8600.
7. Patel A, Gupta VG, Biswas B, Ganguly S, Das CK, Batra A, Bhethanabhotla S. Reply to D.
O'Reilly et al. JCO Global Oncology 2021 :7, 648-648
8. Biswas B, Bakhshi S, Sengupta M. Childhood Ewing sarcoma of orbit: Is it so fatal? J
Pediatr Hematol Oncol. 2016 Jan;38(1):82-3. doi: 10.1097/MPH.0000000000000458.
9. Patel A, Gupta VG, Biswas B, Das CK, Batra A, Ganguly S, Bethanabhotla S. Revisiting
Fulvestrant Dosing in Uncertain Economic Times. JCO Global Oncology no. 7 (2021) 1-3;
DOI: 10.1200/GO.20.00362
10. Batra A, Patel A, Gupta V G, Mehta P, Tilak TVSVGK, Biswas B, Pramanik R, Das C K,
Srivastava P. Oncotype DX: Where Does It Stand in India? Journal of Global Oncology.
July 2019. DOI: 10.1200/JGO.19.00151.
11. Mehta P, Batra A, Patel A, Tannok I, Gupta V G, Tilak TVSVGK, Biswas B, Pramanik R,
Das C K, Drivastava P. Low dose abiraterone in metastatic prostate cancer – is it practice
changing? Facts and Facets. JCO Glob Oncol. 2020 Mar; 6:382-386. doi:
10.1200/JGO.19.00341.
12. Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, Patel A, Bethanabhotla S,
Batra A, Pramanik R, Gupta VG, Das CK, Mahindru S. How we treat lung cancer during
sars-Cov-2 (COVID-19) pandemic in India? Indian Journal of Medical & Pediatric
Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_122_20.
13. Srivastava P, Tilak TVSVGK, Patel A, Das CK, Biswas B, Mahindru S, Pramanik R, Ghosh
J, Mehta P. Advisory for cancer patients during the COVID pandemic. Cancer Res Stat
Treat 2020; 3:145‑8.
14. Batra A, Mehta P, Patel A, Bethanabhotla S, Biswas B, Pramanik R, Das CK. Breast cancer
treatment during the COVID-19 pandemic. Indian Journal of Medical & Pediatric
Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_111_20.
15. Mahindru S, Das CK,Patel A, Mehta P, Biswas B, Batra A, Bandhopadhyay A. Cancer
surgery in challenging time of COVID-19 pandemic – A pragmatic approach. Indian
Journal of Medical & Pediatric Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_121_20.
16. Bethanabhotla S, Pramanik R, Srivastava P, Mehta P,Patel A, Biswas B, Batra A, Gupta VG,
Das CK, Mahindru S. Colorectal cancer chemotherapy during COVID-19 pandemic. Indian
Journal of Medical & Pediatric Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_149_20.
17. Das CK, Mahindru S, Patel A, Batra A, Biswas B, Mehta P, Pramanik R, Bethanabhotla S,
Gupta VG. How I treat epithelial ovarian cancer during COVID-19 pandemic. Indian
Journal of Medical & Pediatric Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_112_20.
18. Pramanik R, Srivastava P, Sharma A, Mehta P, Patel A, Bethanabhotla S, Biswas B, Batra A,
Gupta VG, Das CK, Mahindru S. Management of head-and-neck cancer during COVID-19
crisis: A medical oncology perspective. Indian Journal of Medical & Pediatric Oncology
May 2020; DOI: 10.4103/ijmpo.ijmpo_134_20.
19. Ghosh J, Ganguly S, Biswas B, Dabkara D, Srivastava P, Patel A, Batra A, Mehta P.
Systemic treatment of gastroesophageal cancer during SARS-CoV2. Indian Journal of
Medical & Pediatric Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_118_20.
20. Patel A, Batra A, Mehta P, Sharma A, Sirohi B, Biswas B, Gupta VG, Ganguly S.
Gallbladder cancer: Adjuvant and palliative treatment during Covid-19 pandemic in India.
Indian Journal of Medical & Pediatric Oncology May 2020; DOI:
10.4103/ijmpo.ijmpo_110_20.
21. Dabkara D, Ganguly S, Ghosh J, Patel A, Batra A, Das Ck, Tilak TVSVGK, Biswas B. How
We Treat Genitourinary Cancers During COVID-19 Pandemic? Asian Pacific Journal of
Cancer Care 5(Supplement 1):147-152.
22. Chatterjee A, Biswas B, Gehani A, Das J, Sen S, Mukhopadhyay S, Chandra A, Ghosh P,
Gupta B, Lingegowda D. Oncoradiology preparedness in the COVID-19 pandemic:
Perspective from a tertiary oncology referral center from Eastern India. Indian J Med
Paediatr Oncol; DOI: 10.4103/ijmpo.ijmpo_240_20.
Editorials:
1. Bakshi S, Biswas B. Cytomegalovirus in Hematological Malignancies. Indian Pediatr.
2013; 50 (2):193-94.
2. Bakshi S, Biswas B. Addressing Controversies in Pediatric Oncology. Indian J Pediatr.
2013; 80(10):844-5.
3. Bakshi S, Biswas B. Advances in Pediatric Cancer Therapy: Potential Applicability in Indian
Scenario. Indian J Pediatr. 2015; 82(4):301-2.
Selected summaries:
1. Biswas B, Rastogi S, Batra A, Ganguly S. Trastuzumab and Lapatinib in HER-2-positive
metastatic colorectal cancer. Natl Med J India; 29 (4): 219-220.
2. Biswas B, Dabkara D, Ganguly S. In-transit metastases from Malignant Melanoma. Natl
Med J India. 2017;30(5): 297.
3. Biswas B, Dabkara D, Ganguly S, Prasad E. Consolidation chemotherapy after concurrent
chemoradiotherapy in locally advanced non-squamous non-small cell lung cancer: When,
whom and how much? Natl Med J India; 30 (1): 26-27.
4. Biswas B, Ganguly S, Ghosh J, Batra A. Sodium thiosulfate on development of cisplatin-
induced hearing loss in children with cancer. Natl Med J India. 2017; 30(6): 337- 328.
Case reports:
1. Chatterjee A, Biswas B, Gehani A, Sen S. Pembrolizumab-induced large duct
cholangiopathy: Diagnosis and follow-up imaging. J Postgrad Med 2021;67(1):43-45.
2. Ghosh J, Ganguly S, Dabkara D, Biswas B, Chatterjee A, Mukhopadhyay S, Banerjee S, Sen
S, Arun I. Pancreatic adenocarcinoma with primary tumor calcification and calcified liver
metastasis: Report of a rare case and review of literature. Indian J Med Paediatr Oncol
2020;41:738-740.
3. Ghosh J, Ganguly S, Dabkara D, Biswas B, Chatterjee A, Mukhopadhyay S, Chandra A, Sen
S, Dey D. Metachronous muscle metastasis in a case of metastatic gallbladder cancer with
TP35 gene mutation: A rare case report. South Asian J Cancer. 2019; 8(4): 240-257.
4. Biswas B, Dabkara D, Mukhopadhyay S. Aspergillus Invading Metastatic Cavity? Annals of
Hematology & Oncology, 22 June’2017: 4(7).
5. Ghosh S, Ganguly S, Ghosh J, Biswas B, Dabkara D. A novel oxaliplatin desensitization
protocol: Short, safe, and effective. Indian J Med Paediatr Oncol 2020;41:287-8.
6. Ghosh J, Das J, Ganguly S,, Biswas B, Dabkara D. Cardiac metastasis from squamous
cell carcinoma of the buccal mucosa: A case report and review of the literature.
Cancer Research Statistics and Treatment 3(3):617 - 619.
7. Basu A, Chatterjee M, Ghosh J, Ganguly S, Biswas B, Dabkara D. Leptomeningeal
metastasis in lung cancer: Not always a gloomy picture. Cancer Research Statistics and
Treatment 3(3):619 - 621.
8. Ganguly S, Alphones S, Ghosh P, Midha D, Ghosh J, Biswas B. Rectal cancer with breast
metastasis: A case report with review of literature. Cancer Res Stat Treat 3(3):627 - 629.
9. Basu A, Chatterjee M, Dabkara D, Biswas B, Ganguly S, Ghosh J, Ghosh P. Adrenal
metastasis in an older patient with seminoma. Cancer Res Stat Treat 2020;3:836-7.
10. Biswas B. November 2016- ESMO image of the month. Available at
http://www.esmo.org/Career-Development/Young-Oncologists-Corner/Image-of-the-
Month/November-2016-Image-of-the-Month.
Drug Review:
1. Ganguly S, Ghosh J, Biswas B, Dabkara D. Ado‑trastuzumab emtansine – The
monoclonal drug conjugate in human epidermal growth factor receptor 2‑positive breast
cancer. Indian J Med Paediatr Oncol 2020;41:218-20.
Research Experience (Dr. Bivas Biswas)
1. Study name Role Phase
2. Estimation of Glomerular Filtration Rate in Children from
Prediction Equation Using Plasma Creatinine and Height
PI MD
dissertation
3. Evaluation of clinico-pathological characteristics, prognostic
factors and treatment outcomes of patients with Ewing’s
sarcoma/PNET
PI DM
(fellowship)
dissertation
4. Expression of Cathepsin L in patients with Ewing’s
sarcoma/PNET and its correlation with clinico-pathological
features and outcome- A retrospective study
PI DM
(fellowship)
dissertation
5. A Phase III, randomized, double-blind, placebo-controlled,
multicenter, international study of osimertinib as maintenance
therapy in patients with locally advanced, unresectable EGFR
mutation-positive Non-Small Cell Lung Cancer (Stage III)
whose disease has not progressed following definitive
platinum-based chemoradiation therapy (LAURA)
PI III
6. A Phase III, Randomised, Double-Blind, Placebo-Controlled,
Multicentre Study of Durvalumab as Consolidation Therapy in
Patients with Locally Advanced, Unresectable, Non-Small Cell
Lung Cancer (Stage III) Who Have Not Progressed following
Definitive, Platinum-Based, Chemoradiation Therapy
(PACIFIC- 5)
PI III
7. A Phase III, Double-blind, Placebo-controlled, Multi-center
International Study of Neoadjuvant/ Adjuvant Durvalumab for
the Treatment Patients with Resectable Stages II and III Non-
small Cell Lung Cancer [AEGEAN]
PI III
8. A Phase II, Single Arm Study Assessing the Efficacy of
Osimertinib in Combination with Savolitinib in Patients with
EGFRm+ and MET+, Locally Advanced or Metastatic Non-
Small Cell Lung Cancer who have Progressed Following
Treatment with Osimertinib (The SAVANNAH Study)
PI II
9. A Phase III, Randomized, Double-blind, Placebo-controlled,
Multi-center, International Study of Durvalumab or
Durvalumab and Tremelimumab as Consolidation Treatment
for Patients with Stage I-III Limited Disease Small-Cell Lung
Cancer Who Have Not Progressed Following Concurrent
Chemoradiation Therapy (ADRIATIC)
PI III
10. A Phase III, Randomized, Open-Label, Controlled, Multi-
Center, Global Study of First-Line Durvalumab in Combination
with Standard of Care Chemotherapy and Durvalumab in
PI III
Combination with Tremelimumab and Standard of Care
Chemotherapy Versus Standard of Care Chemotherapy Alone
in Patients with Unresectable Locally Advanced or Metastatic
Urothelial Cancer [NILE]
11. A randomized, open label, multicenter phase II study
evaluating the efficacy and safety of capmatinib (INC280) plus
pembrolizumab versus pembrolizumab alone as first line
treatment for locally advanced or metastatic non-small cell lung
cancer with PD-L1≥ 50% [CINC280I12201]
PI II
12. PARACHUTE: PAzopanib Real-world Assessment of Clinical
effectiveness and safety in patients wHo have Undergone
Treatment in different sEttings in advanced renal cell
carcinoma; a prospective, non-interventional, observational
study (CPZP034AIC04)
PI IV
13. An Open Label, Single Arm, Multicenter, Safety Study of
Atezolizumab in Locally Advanced or Metastatic Urothelial or
Non-Urothelial Carcinoma of the Urinary Tract (MO29983)
PI III
14. An Observational, multicentre, prospective study to evaluate
concordance of detecting EGFR mutation by circulating tumor
free DNA versus tissue biopsy in NSCLC
(CONCORDANCE)
PI observational
15. A Phase III, Open-label, Randomized Study of
Osimertinib with or without Platinum Plus
Pemetrexed Chemotherapy, as First-line Treatment in
Patients with Epidermal Growth Factor Receptor
(EGFR) Mutation- Positive, Locally Advanced or
Metastatic Non-small Cell Lung Cancer
(FLAURA2).
PI III
16. SINGLE ARM STUDY TO EVALUATE THE SAFETY OF
DACOMITINIB FOR THE FIRST LINE TREATMENT OF
PARTICIPANTS IN INDIA WITH METASTATIC NON
SMALL CELL LUNG CANCER WITH EPIDERMAL
GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING
MUTATIONS
PI IV
17. SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF
LORLATINIB IN ALK INHIBITOR-TREATED
UNRESECTABLE ADVANCED AND/OR RECURRENT
ALK-POSITIVE NON-SMALL CELL LUNG CANCER
PARTICIPANTS IN INDIA
PI IV
18. Safety & efficacy of OSIMERTINIB in Indian patients who
progressed after 1st line 1
st or 2
nd generation TKI with T790M
mutation
Co-PI IV
19. Study of Efficacy and Safety of Canakinumab as Adjuvant
Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-
IIIA and IIIB (T>5cm N2) Completely Resected Non-small
Cell Lung Cancer (CANOPY-A)
Co-PI III
20. A randomized, double-blind, placebo-controlled, phase III
study evaluating the efficacy and safety of pembrolizumab plus
platinum-based doublet chemotherapy with or without
canakinumab as first line therapy for locally advanced or
metastatic non-squamous and squamous non-small cell lung
cancer subjects [CANOPY 1]
Co-PI III
21. A Multicenter Phaase 4, Open-label, Single-arm, Safety and
Efficacy Study of Enzalutamide in Indian Patients with
Progressive Metastatic Castration-resistant Prostate Cancer
(mCRPC) Previously Treated with Docetaxel-Based
Chemotherapy [9785-CL-0413]
Co-PI IV
22. An open label, multicenter, non-comparative, Phase IV study
of Panitumumab to characterize its safety, tolerability and
activity in Indian subjects with previously treated wild type
RAS (KRAS and NRAS) metastatic colorectal cancer
Co-PI IV
23. A Phase III Randomised, Double-Blind, Parallel Group,
Multicentre Study to Compare the Efficacy, Safety,
Pharmacokinetics and Immunogenicity between SB3 (proposed
trastuzumab biosimilar) and Herceptin® in Women with Newly
Diagnosed HER2 Positive Early or Locally Advanced Breast
Cancer in Neoadjuvant Setting
Co-PI III
24. A phase III multicenter, randomized study of oral LDK378
versus standard chemotherapy in previously untreated adult
patients with ALK rearranged (ALK-positive), stage IIIB or IV,
non-squamous non-small cell lung cancer (CLDK378A2301).
ASCEND 4
Co-PI III
Signature Date
30-June-2021